NOXOF Stock - Noxopharm Limited
Unlock GoAI Insights for NOXOF
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $2.40M | $6.01M | $5.43M | $5.61M | $8.28M |
| Gross Profit | $-534,811 | $5.86M | $5.17M | $5.35M | $8.04M |
| Gross Margin | -22.3% | 97.4% | 95.2% | 95.3% | 97.1% |
| Operating Income | $-7,535,002 | $-16,595,050 | $-15,207,680 | $-14,609,530 | $-16,366,390 |
| Net Income | $-3,578,117 | $-15,056,373 | $-18,666,810 | $-9,346,749 | $-272,093 |
| Net Margin | -149.1% | -250.5% | -343.9% | -166.7% | -3.3% |
| EPS | $-0.01 | $-0.05 | $-0.06 | $-0.04 | $-0.00 |
Noxopharm Limited, a drug development company, focuses on developing treatment options for a range of solid tumor cancers and septic shock in Australia and internationally. It primarily develops Veyonda, which is an adjuvant therapy in chemotherapy and radiotherapy for the treatment of late-stage cancers. The company also develops DARRT program that is in Phase 1b/2a for the treatment of metastatic castration-resistant prostate cancer and other solid tumors; LuPIN with combined therapy of Veyonda and 177Lu-PSMA-617 for the treatment of late-stage prostate cancer; IONIC program with Veyonda, which is combined with the Bristol Myers Squibb checkpoint inhibitor Opdivo for the treatment of various solid tumor types; and chemotherapy enhancement program (CEP) combined with carboplatin for patients with refractory solid tumors in the breast, head and neck, lung, prostate, and ovaries. In addition, it develops NOXCOVID Program, a dose escalation and dose expansion study of NOX66 for the treatment of COVID-19 infection. Further, the company develops programs to treat pancreatic cancer and glioblastoma. Noxopharm Limited has a collaboration with Hudson Institute of Medical Research and The Australian National University for the research and development of therapeutic drug against inflammatory disorders. The company was incorporated in 2015 and is based in Chatswood, Australia.
Visit WebsiteEarnings History & Surprises
NOXOFEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q3 2025 | Jul 20, 2025 | — | — | — | — |
Q2 2025 | Apr 30, 2025 | — | — | — | — |
Q1 2025 | Feb 25, 2025 | — | — | — | — |
Q3 2024 | Sep 27, 2024 | — | — | — | — |
Q3 2024 | Aug 28, 2024 | — | $-0.00 | — | — |
Q2 2024 | Apr 28, 2024 | — | — | — | — |
Q1 2024 | Feb 26, 2024 | — | $-0.01 | — | — |
Q2 2023 | Jun 30, 2023 | — | $-0.01 | — | — |
Q4 2022 | Dec 30, 2022 | — | $-0.01 | — | — |
Q2 2022 | Jun 30, 2022 | — | $-0.01 | — | — |
Q4 2021 | Dec 30, 2021 | — | $-0.01 | — | — |
Q2 2021 | Jun 30, 2021 | — | $-0.00 | — | — |
Q4 2020 | Dec 30, 2020 | — | $-0.01 | — | — |
Q2 2020 | Jun 30, 2020 | — | $0.02 | — | — |
Q4 2019 | Dec 30, 2019 | — | $-0.02 | — | — |
Q2 2019 | Jun 30, 2019 | — | $-0.02 | — | — |
Q4 2018 | Dec 30, 2018 | — | $-0.01 | — | — |
Q2 2018 | Jun 30, 2018 | — | $-0.02 | — | — |
Q4 2017 | Dec 30, 2017 | — | $-0.05 | — | — |
Q2 2017 | Jun 30, 2017 | — | $-0.02 | — | — |
Latest News
Frequently Asked Questions about NOXOF
What is NOXOF's current stock price?
What is the analyst price target for NOXOF?
What sector is Noxopharm Limited in?
What is NOXOF's market cap?
Does NOXOF pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to NOXOF for comparison